Related Experiment Video
Updated: Aug 11, 2026

Cell-based Assay to Study Antibody-mediated Tau Clearance by Microglia
Published on: November 9, 2018
Endothelial TFEB signaling-mediated autophagic disturbance initiates microglial activation and cognitive dysfunction
Yaping Lu1, Xiang Chen2, Xiuxiu Liu2
1Department of Physiology, School of Basic Medical Sciences, Nanjing Medical University, Nanjing, Jiangsu, China.
Abstract:
Cognitive impairment caused by systemic chemotherapy is a critical question that perplexes the effective implementation of clinical treatment, but related molecular events are poorly understood. Herein, we show that bortezomib exposure leads to microglia activation and cognitive impairment, this occurs along with decreased nuclear translocation of TFEB (transcription factor EB), which is linked to macroautophagy/autophagy disorder, STAT3 (signal transducer and activator of transcription 3) phosphorylation and IL23A (interleukin 23 subunit alpha) expression. Pharmacological enhancement of TFEB nuclear translocation by digoxin restores lysosomal function and reduces STAT3-dependent endothelial IL23A secretion. As a consequence, we found that brain endothelial-specific ablation of Il23a ameliorated both microglia activation and cognitive dysfunction. Thus, the endothelial TFEB-STAT3-IL23A axis in the brain represents a critical cellular event for initiating bortezomib-mediated aberrant microglial activation and synapse engulfment. Our results suggest the reversal of TFEB nuclear translocation may provide a novel therapeutic approach to prevent symptoms of cognitive dysfunction during clinical use of bortezomib.Abbreviations: AAV: adeno-associated virus; BBB: blood-brain barrier; BTZ: bortezomib; DG: digoxin; DGs: dentate gyrus; DLG4/PSD95: discs large MAGUK scaffold protein 4; HBMECs: human brain microvascular endothelial cells; HP: hippocampus; IL23A: interleukin 23 subunit alpha; MBVECs: mouse brain vascular endothelial cells; mPFC: medial prefrontal cortex; NORT: novel object recognition test; OLT: object location test; PLX5622: 6-fluoro-N-([5-fluoro-2-methoxypyridin-3-yl]methyl)-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3- yl)methyl; PPP3/calcineurin: protein phosphatase 3; SBEs: STAT3 binding elements; shRNA: small hairpin RNA; SLC17A7/VGLUT1: solute carrier family 17 member 7; SLC32A1/VGAT: solute carrier family 32 member 1; STAT3: signal transducer and activator of transcription 3, TFEB: transcription factor EB; Ub: ubiquitin.
Insights
Bortezomib chemotherapy causes cognitive impairment by activating microglia. Enhancing TFEB nuclear translocation with digoxin may reverse this, offering a new therapeutic strategy for chemotherapy-induced cognitive dysfunction.
Area of Science:
- Neuroscience
- Molecular Biology
- Pharmacology
Background:
- Chemotherapy-induced cognitive impairment is a significant clinical challenge.
- The underlying molecular mechanisms of chemotherapy-induced cognitive dysfunction remain poorly understood.
- Bortezomib (BTZ) is a chemotherapy agent known to cause side effects, including potential cognitive impairment.
Purpose of the Study:
- To investigate the molecular pathways linking bortezomib exposure to cognitive impairment.
- To identify potential therapeutic targets for mitigating chemotherapy-induced cognitive dysfunction.
- To explore the role of transcription factor EB (TFEB) in bortezomib-mediated neurotoxicity.
Main Methods:
- Utilized mouse models and cell cultures (human brain microvascular endothelial cells) exposed to bortezomib.
- Assessed microglia activation, cognitive function (novel object recognition, object location tests), and molecular markers including TFEB nuclear translocation, STAT3 phosphorylation, and IL23A expression.
- Investigated the effects of pharmacological enhancement of TFEB nuclear translocation using digoxin and genetic ablation of IL23A.
Main Results:
- Bortezomib exposure induced microglia activation and cognitive impairment.
- This was associated with decreased TFEB nuclear translocation, increased STAT3 phosphorylation, and elevated IL23A expression.
- Digoxin treatment restored lysosomal function and reduced IL23A secretion, ameliorating cognitive deficits.
- Brain endothelial-specific ablation of IL23A also reduced microglia activation and cognitive dysfunction.
Conclusions:
- The endothelial TFEB-STAT3-IL23A axis is a critical pathway in bortezomib-induced cognitive impairment.
- Reversing TFEB nuclear translocation represents a potential therapeutic strategy to prevent cognitive dysfunction during bortezomib treatment.
More Related Videos
10:50Visualizing Impairment of the Endothelial and Glial Barriers of the Neurovascular Unit during Experimental Autoimmune Encephalomyelitis In Vivo
Published on: March 26, 2019
08:04Derivation, Expansion, Cryopreservation and Characterization of Brain Microvascular Endothelial Cells from Human Induced Pluripotent Stem Cells
Published on: November 19, 2020
Related Concept Videos
Encephalitis ll: Pathophysiology
Cerebral Edema ll: Pathophysiology
Hepatic Encephalopathy